Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus

Zhongping Zhan¹, Ying Yang¹, Yanfeng Zhan², Dongying Chen¹*, Liuqin Liang¹, Xiuyan Yang¹

¹ Department of Rheumatology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China, ² Department of Obstetrics and Gynecology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

* cdongying@163.com

Abstract

This study aims to investigate the fetal outcomes and associated factors of adverse pregnancy outcomes (APOs) in pregnant women with systemic lupus erythematosus (SLE). Clinical data from 251 SLE patients with 263 pregnancies from 2001 to 2015 were analyzed retrospectively. APOs occurred in 70.0% of pregnancies, in which pregnancy loss occurred in 28.5%; preterm delivery occurred in 21.3%; intrauterine growth retardation occurred in 12.2%; and fetal distress occurred in 8.0%. Over time, the rate of APOs decreased from 82.8% during 2001~2005 to 59.6% during 2011~2015. In multivariate analysis, predictors of APOs included positive antiphospholipid antibodies (OR 8.4, 95% CI 1.7~40.8, \( P = 0.008 \)), lower complement (OR 3.6, 95% CI 1.3~9.9, \( P = 0.01 \)), hypoalbuminemia (OR 3.2, 95% CI 1.2~8.3, \( P = 0.02 \)), and hypertension (OR 14.6, 95% CI 1.5~141.6, \( P = 0.02 \)). The use of antimalarial medications was associated with lower risk for APOs (OR 0.3, 95% CI 0.1~0.7, \( P = 0.01 \)). In total, 109 patients underwent fetal umbilical artery Doppler in the third trimester. The adjusted systole/diastole (S/D) ratio, pulsatility index (PI) and resistance index (RI) of SLE patients with APOs were higher than that of patients without APOs (2.9 ± 0.9 vs. 2.4 ± 0.5, \( P = 0.001 \)). Lupus pregnancy was still at high risk of APOs in terms of pregnancy loss and preterm delivery. Umbilical artery Doppler was a good monitor method for APOs in the third trimester.

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that mainly affects women of reproductive age. Pregnancies in women with SLE resulted in an increase of adverse pregnancy outcomes (APOs) [e.g., stillbirth, premature birth, and intrauterine growth restriction (IUGR)], compared with pregnancies in healthy women[1–3]. Several risk factors of APOs in SLE pregnancies have been identified, such as proteinuria, antiphospholipid
syndrome (APS), thrombocytopenia, and anti-SSA/Ro antibody [4–6]; but results were varied and controversial. Moreover, previous epidemiological studies demonstrated that Asian SLE patients had higher clinical severity than non-Asian SLE patients [7], while the effects of lupus on the pregnancy outcomes in China still had limited data. In China, fetal Doppler ultrasound examinations were regularly performed during each trimester in all pregnancies. The predictive value of fetal Doppler ultrasound examinations for APOs has been reported. Several studies have demonstrated that abnormal umbilical blood flow was correlated with an increased risk of pre-eclampsia and fetal growth restriction in the general population. The close surveillance could be used to manage the best time of delivery in high-risk patients [8]; while the predictive value of Doppler ultrasound of fetal umbilical artery in lupus pregnancies has not been widely assessed.

We therefore conducted a retrospective study based on a large number of patients during the last 15 years. The objectives of this study were to (1) determine the frequency of APOs in Chinese patients with SLE; (2) explore clinical and laboratory variables that predict APOs; and (3) ascertain the predictive value of Doppler ultrasound of fetal umbilical artery for fetal outcomes in SLE pregnancies.

**Materials and methods**

**Study design and patients**

We performed a retrospective review of medical records from consecutive SLE patients with pregnancy in the First Affiliated Hospital of Sun Yat-Sen University from 2001 to 2015. Women with SLE fulfilled the 1997 American College of Rheumatology revised criteria for SLE [9]. The outcomes of the pregnancies were systematically checked. Patients with incomplete medical records were excluded. The study was reviewed and approved by Medical Ethical Committee of the First Affiliated Hospital of Sun Yat-San University.

**Data collection**

Information was obtained from patients’ recorded data, including demographic data, lupus activity during the first, second, and third trimesters of pregnancy, blood pressure, laboratory data, treatment during pregnancy, and outcomes. Laboratory data included complete blood count, urinalysis, serum albumin, 24-hour proteinuria, complement C3 and C4, antinuclear antibody (ANA), anti-dsDNA antibody, anti-SSA/Ro, and anti-SSB/La. Tests for antiphospholipid (aPL) antibodies included anticardiolipin antibodies (aCL, aCL-IgG, and aCL-IgM), anti-β2-glycoprotein I antibodies, and lupus anticoagulant. All laboratory tests were performed according to standard methods.

The first trimester of pregnancy was termed before the end of the 12th week of gestation; the second trimester was defined between the 13th and the end of the 27th week; and the third trimester was the last three months of gestation. Hypertension was defined as systolic >140 mmHg and/or diastolic blood pressure >90 mmHg in sitting position in at least two consecutive measurements during pregnancy or the usage of anti-hypertensive drugs. Hypoalbuminemia was defined as serum albumin less than 35g/L. The disease activity of SLE during pregnancy was assessed by SLE pregnancy disease activity index, and active SLE was considered when the scores were equal to or more than 4 [10]. The highest index during pregnancy before delivery was considered.

We first defined “lupus relapse” in the method section: lupus relapse was defined as has been suggested in a recent International Consensus [11]: new onset or worsening of specific and associated cutaneous manifestations of SLE, arthritis, one or more hemocytopenias not attributed to immunosuppressive drugs, neurological, cardiopulmonary and renal...
manifestations, elevated serum creatinine in association with low serum complement and/or elevated titers of anti-dsDNA antibodies.

Doppler ultrasound examinations of fetal umbilical artery

A fetal Doppler ultrasound examination was performed on all fetuses during the 28th–34th gestational weeks using Voluson E6 (GE Kretztechnik, USA) machine equipped with a 4–8 MHz transabdominal probe. Patients were placed in a semi-recumbent position with a left lateral tilt. Then, using a pulsed wave Doppler on a free loop of the cord, the characteristic sound and shape of the umbilical artery were identified. The Doppler flow parameters of umbilical arteries were recorded, including pulsatility index (PI), resistance index (RI), the peak value of umbilical arteries at end-systole (Vmax, also abbreviate as S) and the peak value of umbilical arteries at end-diastole (Vmin, also abbreviate as D). When the screen showed at least three consecutive wave forms of similar height, the image was frozen, and the Doppler PI of the umbilical artery was estimated. A minimum of three separate readings were averaged before the final values were calculated. S/D ratio (i.e., Vmax/Vmin) was calculated automatically. The values (RI, PI and S/D) was adjusted according to the gestational age at examination. Doppler studies of umbilical artery were avoided during fetal activity and breathing because of the effect of fetal breathing movements on waveform variability.

APOs

The study-defined APOs included one or more of the following: 1) pregnancy loss, including spontaneous abortion (termination of pregnancy before 20 weeks of gestation caused by natural factors), therapeutic abortion (artificial termination of pregnancy because of life-threatening progression of lupus or obstetric complications), and fetal death (intrauterine fetal demise after 20 weeks of gestation unexplained by chromosomal abnormalities, anatomic malformation, or congenital infection); neonatal death referred to the death of a live infant within 28 days after birth; 2) premature birth (live birth before 37 weeks of gestation); 3) IUGR (birth weight below the 10th percentile of Chinese population according to gestational week at delivery and fetal gender; and 4) fetal distress referred to fetus hypoxia and acidosis, which could endanger the health of the fetus.

Statistical analysis

Statistical analysis was performed using SPSS 20.0 software. Quantitative variables were described as mean ± standard deviation using t-test to compare two groups. Categorical variables were described as frequency and percentage. Two-by-two tables were analyzed by chi-square or Fisher exact test, as appropriate. Factors related to APOs at P<0.10 in univariate analyses were entered into a multivariate logistic model. A P-value of <0.05 was considered statistically significant.

Ethics statement

The study was reviewed and approved by Medical Ethical Committee of the First Affiliated Hospital of Sun Yat-San University. Since this is a retrospective study, the Ethical Committee waived that the research could be done based on record review without contacting the patients. Support letter was obtained from the medical director office of the hospital for retrieving retrospective data from the database and records. All the information was kept confidential, and no individual identifiers were collected.
Results

Clinical characteristics

Clinical records for 251 SLE patients with 263 pregnancies were reviewed. The 240 women each had one pregnancy, 10 women each had two pregnancies, and 1 had three pregnancies. The sample had a mean age of 28.6±3.9 years at pregnancy. Among the 263 pregnancies, 75 were newly diagnosed with SLE during pregnancy, and 188 were previously diagnosed with SLE, including 149 planned and 39 unplanned pregnancies. The mean disease duration of patients with previously diagnosed SLE was 69.9±46.8 months (3~252 months). Of all pregnancies, 141 (53.6%) had active lupus during pregnancy. The most common complication was lupus nephritis, which was identified in 53.6%; followed by thrombocytopenia in 20.9%, heart involvements in 6.5%, lung involvements in 6.1%, and digestive system involvements in 3.0%. Fourteen patients had antiphospholipid syndrome (14/251, 5.6%), 6 of them received aspirin alone during pregnancy, and 8 were treated with aspirin and low molecular weight heparin. While the treatments of aspirin or heparin could not modify the outcome of pregnancies. In terms of immunosuppressants, there was no difference between pregnancies with or without APOs (Table 1). We noted that 52 (52/188, 27.7%) pregnancies were complicated by at least one episode of lupus relapse during their pregnancy. The relapse rate was not different in each trimester.

Table 1. Association of different characteristics during pregnancy with APOs: Results of univariate analysis.

| Characteristics                              | Total (n = 263) | With APOs (n = 159) | Without APOs (n = 104) | P value |
|----------------------------------------------|----------------|---------------------|------------------------|---------|
| Medical history (n, %)                       |                |                     |                        |         |
| Prior lupus nephritis history                | 66 (25.1)      | 46 (28.9)           | 20 (19.2)              | 0.08    |
| Prior APOs history                           | 99 (37.6)      | 61 (38.4)           | 38 (36.5)              | 0.8     |
| Clinical manifestation (n, %)                |                |                     |                        |         |
| SLEPDAI>4 during pregnancy                  | 141 (53.6)     | 112 (70.4)          | 29 (27.9)              | <0.001  |
| Active lupus nephritis                      | 111 (42.2)     | 100 (62.9)          | 11 (10.6)              | <0.001  |
| Thrombocytopenia                            | 55 (20.9)      | 42 (26.4)           | 13 (12.5)              | 0.007   |
| Leukopenia                                  | 16 (6.1)       | 14 (8.8)            | 2 (1.9)                | 0.02    |
| Skin rash                                   | 51 (19.4)      | 36 (22.6)           | 15 (14.4)              | 0.1     |
| Joint involvement                           | 31 (11.9)      | 23 (14.5)           | 8 (7.7)                | 0.1     |
| Hypertension                                | 50 (19.0)      | 44 (27.7)           | 6 (5.8)                | <0.001  |
| Lab data (n, %)                              |                |                     |                        |         |
| ANA positivity                               | 238 (90.5)     | 147 (92.5)          | 91 (87.5)              | 0.2     |
| Anti-dsDNA antibody positivity              | 179 (68.1)     | 118 (74.2)          | 61 (58.7)              | 0.008   |
| Anti-Ro antibody positivity                 | 102 (38.8)     | 73 (45.9)           | 29 (27.9)              | 0.003   |
| Anti-La antibody positivity                 | 36 (13.7)      | 26 (16.4)           | 10 (9.6)               | 0.1     |
| Antiphospholipid antibodies positivity      | 56 (24.9)      | 51 (38.6)           | 5 (5.4)                | <0.001  |
| Hypoalbuminemia                             | 136 (51.7)     | 109 (68.6)          | 27 (26.0)              | <0.001  |
| Hypocomplementemia                          | 100 (38.0)     | 84 (52.8)           | 16 (15.4)              | <0.001  |
| Medication during pregnancy (n, %)          |                |                     |                        |         |
| Isodose of prednisone >15mg/d               | 114 (43.3)     | 95 (60.7)           | 19 (18.3)              | <0.001  |
| Hydroxychloroquine                          | 87 (33.1)      | 39 (24.5)           | 48 (46.2)              | <0.001  |
| Aspirin                                     | 14 (5.3)       | 10 (6.3)            | 4 (3.8)                | 0.6     |
| Low molecular weight heparin                | 8 (3.0)        | 7 (4.4)             | 1 (1.0)                | 0.2     |
| Azathioprine                                | 12 (4.6)       | 8 (5.0)             | 4 (3.8)                | 0.8     |
| Cyclosporin                                 | 5 (1.9)        | 4 (2.5)             | 1 (1.0)                | 0.7     |

https://doi.org/10.1371/journal.pone.0176457.t001
Fetal outcomes

A total of 188 live births (71.5%) and 75 pregnancy loss (28.5%) were recorded in the study. One or more APOs occurred in 70.0% (184/263) of patients with SLE. Twenty-five patients (10.0%) had more than one outcome (Table 2). Pregnancy loss and premature births were the most common APOs. Moreover, 12 neonates were diagnosed with neonatal lupus, 9 of which had facial or trunk rash and cardiac involvement, respectively. Among the mothers of 12 neonates with neonatal lupus, 5 of whom were only anti-Ro positive, and 5 were both anti-Ro and anti-La positive. Six congenital malformations included one cleft lip and palate, one stenopodia, one polydactyly, two ventricular septal defects, and one atrial septal defect. For those neonates with congenital malformations, all of them did not receive any teratogenic drugs. In this study, pregnancy induced hypertension (PIH) occurred in 35 cases, of which, 3 cases were gestational hypertension and 32 were preeclampsia. There was no eclampsia occurred.

Time trends of specific APOs

The constituent ratio of specific APOs had a great change across different time periods. The rate of APOs decreased from 82.8% during 2001~2005 to 59.6% during 2011~2015. Over time, the rate of pregnancy loss decreased, while the proportion of pregnancies resulting in live birth increased. The frequency of fetal distress and IUGR decreased. The rate of premature birth reached its highest point in the second five years and reduced thereafter (Fig 1, Table 3).

Clinical features and risk factors of pregnancy loss

In terms of causes of pregnancy loss, therapeutic abortion was predominant, followed by spontaneous abortion, stillbirth, and neonatal death (Table 4). Univariate analysis revealed that nephritis, active lupus, thrombocytopenia, leukopenia, hypocomplementemia, low serum albumin level, aPL positive, ANA positive, and non-use of hydroxychloroquine (HCQ) were associated with pregnancy loss (Table 4). In multivariate analysis, active lupus (OR 12.4, 95% CI = 3.9–39.1, P < 0.001) and aPL positive (OR 2.9, 95% CI = 1.2–6.8, P = 0.01) were independent predictors for pregnancy loss.

Table 2. Fetal outcomes in pregnant women with SLE.

|                      | N  | %   |
|----------------------|----|-----|
| Live birth (n, %)    | 188| 71.5|
| Full-term birth (n, %)| 132| 70.2|
| Premature birth (n, %)| 56 | 21.0|
| Intrauterine growth retardation (n, %) | 32 | 12.2|
| Fetal distress (n, %) | 21 | 8.0 |
| Neonatal lupus erythematous (n, %) | 12 | 4.6 |
| Pregnancy loss (n, %) | 75 | 28.5|
| Spontaneous abortion (n, %) | 18 | 6.8 |
| Therapeutic abortion (n/N, %)* | 48 | 18.3|
| Stillbirth (n, %)     | 7  | 2.7 |
| Neonatal death (n, %) | 2  | 0.8 |

* Forty-two for severe SLE complications during pregnancy, including 28 lupus nephritis (LN), 8 multiple involvements (3 with LN and diffuse alveolar hemorrhage, 2 with LN and neuropsychiatric lupus, 1 with LN and lupus mesenteric vasculitis, and 2 with LN and pulmonary hypertension), 6 severe thrombocytopenia, two for usage of thalidomide before pregnancy, and four for personal reasons.

https://doi.org/10.1371/journal.pone.0176457.t002
Fig 1. The rate of adverse pregnancy outcomes in women with SLE over the past 15 years.

Table 3. The time trend of APOs in women with SLE over the past 15 years.

| Year       | Pregnancies N | Live birth N | APOs N(%) | Pregnancy loss N (%) | Premature birth N (%) | IUGR N (%) | Fetal distress N (%) |
|------------|----------------|--------------|-----------|----------------------|-----------------------|------------|----------------------|
| 2001~2005  | 64             | 36           | 53 (82.8) | 28 (43.8)            | 10 (27.8)             | 7 (19.4)   | 8 (22.2)             |
| 2006~2010  | 85             | 63           | 63 (74.1) | 22 (25.9)            | 22 (34.9)             | 12 (19.1)  | 7 (11.1)             |
| 2011~2015  | 114            | 89           | 68 (59.6) | 25 (21.9)            | 24 (26.9)             | 13 (14.6)  | 6 (6.7)              |
| Total      | 263            | 188          | 184 (70.0)| 75 (28.5)            | 56 (29.8)             | 32 (17.0)  | 21 (11.2)            |

Table 4. Demographic, laboratory, clinical manifestations of SLE pregnancies with or without pregnancy loss.

| Characteristics                        | Pregnancy loss (n = 75) | Without pregnancy loss (n = 188) | P Value |
|----------------------------------------|-------------------------|----------------------------------|---------|
| Age of mother (yrs), mean±SD           | 27.6±4.1                | 28.3±3.5                         | 0.2     |
| SLEPDAI>4, n (%)                       | 70(93.3)                | 71 (37.8)                        | <0.001  |
| Active lupus nephritis, n (%)          | 55(73.3)                | 56(29.8)                         | <0.001  |
| Leukopenia, n (%)                      | 11 (14.7)               | 5 (2.7)                          | <0.001  |
| Thrombocytopenia, n (%)                | 28 (37.3)               | 27 (14.4)                        | <0.001  |
| Skin rash, n (%)                       | 18 (24.0)               | 29 (15.4)                        | 0.1     |
| Hypertension, n (%)                    | 13 (17.3)               | 37 (19.7)                        | 0.7     |
| ANA positivity, n (%)                  | 73 (97.3)               | 165 (87.8)                       | 0.02    |
| Anti-dsDNA positivity, n (%)           | 61 (81.3)               | 118 (62.8)                       | 0.004   |
| aPL positivity, n (%)                  | 29 (38.8)               | 27 (14.4)                        | <0.001  |
| Hypocomplementemia, n (%)              | 54 (72.0)               | 46 (24.5)                        | <0.001  |
| Hypoalbuminemia, n (%)                 | 59 (78.7)               | 77 (41.0)                        | <0.001  |
| Isodose of prednisone >15mg/d, n (%)   | 8 (10.7)                | 4 (2.1)                          | 0.003   |
| Hydroxychloroquine, n (%)              | 16 (21.3)               | 71 (37.8)                        | 0.01    |
Clinical features and risk factors of preterm deliveries

Among the 188 live deliveries, 56 (29.8%) delivered preterm. The rates of preterm delivery before and after 34 weeks were 39.3% and 60.7%, respectively. Iatrogenic preterm delivery, preterm premature rupture of membranes, and spontaneous preterm births contributed to 38 (67.9%), 10 (17.9%) and 8 (14.3%) of preterm births, respectively. Two preterm neonatus died with the neonatal mortality rate of 3.6%, both of which occurred in those delivered <34 weeks; one for severe asphyxia with ventricular septal defect, and one for neonatal respiratory distress syndrome. As shown in Table 5, SLE patients with preterm delivery had a higher frequency of active lupus, renal involvement, thrombocytopenia, aPL positive, hypocomplementemia, and hypoalbuminemia, as well as hypertension, than SLE patients with full term delivery. Moreover, patients with preterm delivery received higher rate of >15mg/d prednisone and less rate of hydroxychloroquine. In multivariate analysis, hypertension (OR 5.7, 95% CI 2.4–13.5, \(P<0.001\)) and hypoalbuminemia (OR 4.1, 95% CI 1.7–9.8, \(P = 0.002\)) were risk factors for preterm delivery.

Clinical features and APOs of new onset SLE during pregnancy

Fifty-three patients with new onset lupus developed APOs (34 with pregnancy loss, 15 with premature, 8 with IUGR, 5 with fetal distress and 5 with neonatal lupus). The main SLEPDAI scores of patients with new-onset SLE was 12.0±8.0. Among the patients who became pregnant after the diagnosis of SLE (also known as “non new-onset lupus”), 106 APOs occurred during pregnancy (41 with pregnancy loss, 41 with premature, 24 with IUGR,16 with fetal distress and 7 with neonatal lupus). The percentage of non new-onset lupus patients with pre-conception activity was 7.4% (14/188). At the time of conception, 158 cases had prednisone (mean dose 8.5±7.1mg/d, range 2.5–60mg/d), 53 women had hydroxychloroquine, 5 had azathioprine, 1 had cyclosporin and 4 had aspirin.

Associated factors of APOs

The proportions of active lupus, lupus nephritis, thrombocytopenia, leukopenia, and hypertension were significantly higher in patients with APOs. Compared with patients without APOs, those with APOs had a lower serum albumin and complementary level. Mothers with

| Characteristics | Preterm deliveries (n = 56) | Full term deliveries (n = 132) | P Value |
|-----------------|-----------------------------|-------------------------------|---------|
| Age of mother (yrs), mean±SD | 28.9±3.9 | 29.1±3.3 | 0.7 |
| SLEPDAI>4, n (%) | 37 (66.1) | 35 (26.5) | <0.001 |
| Active lupus nephritis, n (%) | 32 (57.1) | 24 (18.2) | <0.001 |
| Thrombocytopenia, n (%) | 14 (25.0) | 13 (9.8) | 0.007 |
| Skin rash, n (%) | 10 (17.9) | 17 (12.9) | 0.4 |
| Hypertension, n (%) | 24 (42.9) | 15 (11.4) | <0.001 |
| ANA positivity, n (%) | 53 (94.6) | 113 (85.6) | 0.08 |
| Anti-dsDNA positivity, n (%) | 40 (71.4) | 78 (59.1) | 0.1 |
| aPL positivity, n (%) | 20 (35.7) | 12 (9.1) | <0.001 |
| Hypocomplementemia, n (%) | 27 (48.2) | 19 (14.4) | <0.001 |
| Hypoalbuminemia, n (%) | 47 (83.9) | 30 (22.7) | <0.001 |
| Isodose of prednisone >15mg/d, n (%) | 29 (51.8) | 22 (16.7) | <0.001 |
| Hydroxychloroquine, n (%) | 12 (21.4) | 53 (40.2) | 0.01 |

https://doi.org/10.1371/journal.pone.0176457.t005
APOs were more likely to be positive to anti-dsDNA, anti-Ro, and aPL antibodies. Rates of use of prednisone >15mg/d and antimalarial medications also differed between those with or without APO (Table 1). According to multivariate regression analysis, variables that were independently predictive of APOs at any time included aPL antibodies status (OR 8.4, 95% CI 1.7–40.8, \( P = 0.008 \)), lower complement (OR 3.6, 95% CI 1.3–9.9, \( P = 0.01 \)), hypoalbuminemia (OR 3.2, 95% CI 1.2–8.3, \( P = 0.02 \)), and hypertension (OR 14.6, 95% CI 1.5–141.6, \( P = 0.02 \)). Use of antimalarial medications (OR 0.3, 95% CI 0.1–0.7, \( P = 0.01 \)) was associated with lower risk for APOs.

Fetal umbilical artery Doppler

A total of 109 patients underwent fetal umbilical artery Doppler at 28–34 weeks of gestation. Among these pregnancies, 65 ended in fetal APOs: 20 with preterm delivery, 19 with IUGR, 17 with fetal distress, 7 with stillbirth, and 2 with neonatal death. The examination times of fetus with and without APOs were similar (respectively 31.1 \( \pm \) 1.6 and 31.7 \( \pm \) 1.5 gestational weeks, \( P = 0.7 \)). Fetus with APOs had higher S/D ratio, higher PI as well as higher RI compared with fetus without APOs (Table 6).

Discussion

Our study indicated that lupus pregnancy still holds an increase in risk of APOs in terms of pregnancy loss and preterm births, especially in a setting of ethnic race with more disease severity. Studies of APOs in SLE showed significant variation with respective study design and APO definitions. Making direct comparisons between single-center studies was difficult. The similar rate of APOs was observed in a meta-analysis by Smyth et al.\(^{[12]}\). In the research, 37 studies with 1,842 patients and 2,751 pregnancies were included. The rates of unsuccessful pregnancy and premature birth rate were 23.4% and 39.4%, respectively. Another multi-center prospective study showed that lower rate of APOs occurred in 22.0% of SLE pregnant patients\(^{[13]}\).

Early studies reported that pregnancy with SLE resulted in poor fetal outcomes. In contrast, our study showed that the outcomes of pregnancy with SLE were improving over time. The similar trend was also observed by Moroni et al.\(^{[14]}\) and Cortés-Hernández et al.\(^{[15]}\). These improvements may reflect the progress in maternal disease control and the emergence of new therapeutic options. European League Against Rheumatism recommended HCQ to be used during lupus pregnancies since 2007\(^{[16]}\). HCQ has been reported to reduce the risk of lupus flare-up during pregnancy\(^{[17]}\), and decrease the rate of neonatal cardiac involvement\(^{[18]}\), prematurity, and IUGR\(^{[19]}\). An increased use of HCQ during pregnancy since 2005, from 6.3% in the first five years to 60.9% in the third five years, was also observed in our study, which might be another reason for the improvement of outcomes.
Our study from South China showed that 28.5% of pregnancies ended in pregnancy loss. In studies published after 2000, pregnancy loss ranged between 13% and 35% in mothers with lupus[20–22], which is the most frequent complication of pregnancies in SLE. Therapeutic abortion accounted for more than half of pregnancy loss in our study. SLE activity and aPL increased the rate of pregnancy loss. Previous reports pointed out an increased risk in fetal loss if the mothers had circulating aPL[23, 24]. Besides aPL, SLE activity was also associated with fetal loss[25]. Overall, this data suggested that maintaining inactive disease at and during pregnancy, as well as treating with positive aPL, is important for a successful pregnancy.

Preterm birth was the main cause of perinatal mortality and long-term morbidity. The crude preterm birth rate was 21.3% in our cohort, which was similar to the findings of other studies[26, 27], but higher than the rate estimated in healthy Chinese women (6.2%–7.2%) [28]. In our series, preterm births were frequently related to iatrogenic as option to protect the health of mothers and fetus. Our data indicated that the majority of preterm births occurred between 34 and 37 weeks of gestation. Two neonatal deaths both occurred in those delivered in <34 weeks, so voluntary interruption of pregnancy before this point should be carefully discussed between physicians and the family. Several factors have been reported to be associated with preterm deliveries. However, a consensus has not been established regarding these factors. We found that hypertension and hypoalbuminemia were risk factors for preterm delivery. A systematic review also confirmed the significant link between maternal hypertension during pregnancy and the rate of premature birth[29]. Earlier, Molad et al. had reported that adverse live-birth outcomes were significantly associated with lower serum albumin level.

Our data indicated that serologic activity (positive for aPL, low complement level, or hypoalbuminemia) and hypertension were independent risk factors predisposing to APOs. This finding was comparable to those obtained in previous studies[30–32]. As for drug administration, HCQ treatment was associated with lower risk of APOs. Other groups have reported the protective effect of HCQ in SLE pregnancy. Our study highlighted the importance of disease control and the use of HCQ to reduce the onset of APOs. Nonetheless, obtaining optimal outcomes of SLE pregnancy remains a challenge.

In this study, we demonstrated that adjusted three indices (S/D, PI, RI) of the third trimester were relatively higher in those with later APOs. Studies about Doppler ultrasound examination of umbilical arteries in SLE pregnancies are limited. A study from France found that an abnormal umbilical artery waveform on second trimester Doppler examination was the best predictor for APOs in SLE and/or APS[33]. In 77 APS pregnancies, Carmona et al. found that fetal outcome correlated with abnormal Doppler examination of umbilical artery at 23–26 weeks[34]. Our results demonstrated that fetal umbilical artery Doppler could be used to stratify the standard of care in pregnancy with SLE; women with abnormal indices of fetal umbilical artery Doppler could start strict monitoring to rapidly identify and treat obstetric complications. However, the findings should be assessed in larger prospective studies.

The study had its own limitations as a retrospective study, such as selection bias, information bias, and small sample size. Given the fetal umbilical artery Doppler, we only performed in the third trimester. The predictive value of fetal umbilical artery Doppler in lupus pregnancies should be also assessed in the first and second trimester.

In conclusion, many pregnant women with SLE may have successful outcomes, but they still remain at an increased risk in terms of pregnancy loss and preterm deliveries. Pregnancy outcomes in our patients have improved during a 15-year period because of the progress of management of SLE and pregnancy. Pregnancy loss remains an important issue, particularly for patients with positive aPL and active lupus activity during pregnancy. Preterm births at <34 weeks of gestation were monitored the most. SLE activity and hypertension influenced pregnancy outcomes. HCQ was safe and prevented APOs of SLE pregnancies. Based from the
data from our study, Doppler assessment of umbilical artery in the third trimester was a meaningful monitoring method in pregnant women with lupus.

**Author Contributions**

**Conceptualization:** LL XY.

**Formal analysis:** ZZ YY DC.

**Funding acquisition:** ZZ DC.

**Investigation:** YZ YY.

**Methodology:** LL XY.

**Project administration:** ZZ XY DC.

**Resources:** YZ YY.

**Supervision:** ZZ DC.

**Visualization:** ZZ DC.

**Writing – original draft:** ZZ DC.

**Writing – review & editing:** ZZ DC.

**References**

1. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060–2068. [https://doi.org/10.2215/CJN.00240110 PMID: 20888887](https://doi.org/10.2215/CJN.00240110 PMID: 20888887)

2. Piccoli GB, Minelli F, Versino E, Cabiddu G, Attini R, Vigotti FN, et al. Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes. Nephrol Dial Transplant 2016; 31:1915–1934. [https://doi.org/10.1093/ndt/gfv395 PMID: 26614270](https://doi.org/10.1093/ndt/gfv395 PMID: 26614270)

3. Moroni G, Doria A, Giglio E, Tani C, Zen M, Strigini F, et al. Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 2016; 74:6–12 [https://doi.org/10.1016/j.jaut.2016.07.010 PMID: 27496151](https://doi.org/10.1016/j.jaut.2016.07.010 PMID: 27496151)

4. Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153–163. [https://doi.org/10.7326/M14-2235 PMID: 26098843](https://doi.org/10.7326/M14-2235 PMID: 26098843)

5. Al AA, Khalil N. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia. Lupus 2010; 19: 1665–1673. [https://doi.org/10.1177/0961203310378669 PMID: 20947541](https://doi.org/10.1177/0961203310378669 PMID: 20947541)

6. de Jesus GR, Mendoza-Pinto C, de Jesus NR, Dos SF, Klumb EM, Carrasco MG, et al. Understanding and Managing Pregnancy in Patients with Lupus. Autoimmune Dis 2015; 2015: 943490. [https://doi.org/10.1155/2015/943490 PMID: 26246905](https://doi.org/10.1155/2015/943490 PMID: 26246905)

7. Jakes RW, Bae SC, Loufrenno W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012; 64: 159–168.

8. Le Thi HD, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45: 332–338.

9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

10. Buyon JP, Kalunian KC, Ramsey-Goldman R, Petri MA, Lockshin MD, Ruiz-Instorza G, et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999; 8: 677–684. [https://doi.org/10.1191/096123999680411272 PMID: 10568906](https://doi.org/10.1191/096123999680411272 PMID: 10568906)
11. Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P, et al. International consensus for a definition of disease flare in lupus. Lupus 2011; 20: 453–462. https://doi.org/10.1177/0961203310388445 PMID: 21148601

12. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060–2068. https://doi.org/10.2215/CJN.00240110 PMID: 20688887

13. Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016; 214: 101–108.

14. Moroni G, Quaglini S, Banfi G, Caloni M, Finazzi S, Ambroso G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis 2002; 40: 713–720. https://doi.org/10.1053/ajkd.2002.35678 PMID: 12324905

15. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarrés M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 2002; 41: 643–650.

16. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67: 195–205. https://doi.org/10.1136/ard.2007.070367 PMID: 17504841

17. Clowse MEB, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis & Rheumatism 2006; 54: 3640–3647.

18. Lateef A, Petri M. Managing lupus patients during pregnancy. Best Practice & Research Clinical Rheumatology 2013; 27: 435–447.

19. Leroux M, Desveaux C, Parcevaux M, Julliac B, Gouyon JB, Dallay D, et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24: 1384–1391 https://doi.org/10.1177/0961203315591027 PMID: 26082465

20. Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford) 2000; 39: 1014–1019.

21. Saavedra MA, Cruz-Reyes C, Vera-Lastra O, Romero GT, Cruz-Cruz P, Arias-Flores R, et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol 2012; 31: 813–819. https://doi.org/10.1007/s10067-012-1941-4 PMID: 22278163

22. Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20: 829–836. https://doi.org/10.1177/0961203310397967 PMID: 21543513

23. Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153–163. https://doi.org/10.7326/M14-2235 PMID: 26098843

24. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005; 52: 514–521. https://doi.org/10.1002/art.20864 PMID: 15692988

25. Madazli R, Yuksel MA, Oncul M, Imamoglu M, Yilmaz H. Obstetric outcomes and prognostic factors of lupus pregnancies. Arch Gynecol Obstet 2014; 289: 49–53. https://doi.org/10.1007/s00404-013-2935-4 PMID: 23807699

26. Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol 2003; 30: 2127–2132. PMID: 14528505

27. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33: 237–252. https://doi.org/10.1016/j.rdc.2007.01.002 PMID: 17499705

28. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012; 379: 2162–2172. https://doi.org/10.1016/S0140-6736(12)60820-4 PMID: 22682464

29. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060–2068. https://doi.org/10.2215/CJN.00240110 PMID: 20688887

30. Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153–163. https://doi.org/10.7326/M14-2235 PMID: 26098843

31. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011; 38: 1012–1016. https://doi.org/10.3899/jrheum.100746 PMID: 21406496
32. Clowse ME, Wallace DJ, Weisman M, James A, Criscione-Schreiber LG, Pisetsky DS. Predictors of preterm birth in patients with mild systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 1536–1539. https://doi.org/10.1136/annrheumdis-2012-202449 PMID: 23361085

33. Le Thi HD, Wechsler B, Vauthier-Brouzes D, Duhaut P, Costedoat N, Andreu MR, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford) 2006; 45: 332–338.

34. Carmona F, Font J, Azulay M, Creus M, Fabregues F, Cervera R, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46: 274–279. PMID: 11642676